Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial

Critical Care Medicine

Volumn 26, Issue 12, 1998, Pages 1963-1971

  Dhainaut, Jean François A ^a   Tenaillon, Alain ^b   Hemmer, Margaret ^c   Damas, Pierre ^d   Le Tulzo, Yves ^e   Radermacher, Peter ^f   Schaller, Marie Denise ^g   Sollet, Jean Pierre ^h   Wolff, Michel ⁱ   Holzapfel, Laurent ^j   Zeni, Fabrice ^k   Vedrinne, Jean Marc ^l   De Vathaire, Florent ^m   Gourlay, Marie Laurence ⁿ   Guinot, Philippe ⁿ   Mira, Jean Paul ^a  

^a Université Paris Descartes   (France)

^b L Michel University Hospital   (France)

^c University Hospitals   (Luxembourg)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h CENTRE HOSPITALIER VICTOR DUPOUY   (France)

ⁱ BICHAT HOSPITAL   (France)

^j Bourg en Bresse Hospital   (France)

^k SERVICE DE NEUROLOGIE   (France)

^l EDOUARD HERRIOT HOSPITAL   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ IPSEN   (France)

more..

Author keywords

Clinical trials; Critical illness; Gram negative bacterial infection; Inflammation; Mortality rate; Multiple organ failure; Platelet activating factor; Randomized controlled trials; Sepsis; Sepsis syndrome; Septic shock

Indexed keywords

GINKGOLIDE B; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; ANALYSIS OF VARIANCE; APACHE; DITERPENES; DOUBLE-BLIND METHOD; FREE RADICAL SCAVENGERS; GINKGOLIDES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LACTONES; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS;

EID: 0032433468     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199812000-00021     Document Type: Review

References (45)

1. Feuerstein G, Hallenbeck JM: Prostaglandins, leukotrienes and platelet activating factor in shock. Annu Rev Pharmacol Toxicol 1987; 27:301-313
2. Braquet P, Paubert-Braquet M, Bourgain RH, et al: Platelet-activating factor/cytokines autoregulated feedback networks in microvascular injury: Consequences in shock, ischemia and graft rejection. J Lipid Med 1989; 1:75-112
3. Myers AK, Robey JW, Price RM: Relationships between tumor necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br J Pharmacol 1990; 99:499-502
4. Serhan CN, Haeggström JZ, Leslie CC: Lipid mediator networks in cell signaling: Update and impact of cytokines. FASEB J 1996; 10:1147-1158
5. Bussolino F, Porcellini MG, Varese L, et al: Intravascular release of platelet activating factor in children in sepsis. Thromb Res 1987; 48:619-620
6. Diez FL, Nieto M, Fernandez-Gallardo S, et al: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 1989; 83:1733-1740
7. Leaver HA, Qu JM, Smith G, et al: Endotoxin releases platelet-activating factor from human monocytes in vitro. Immunopharmacology 1990; 20: 105-113
8. Cabellos C, MacIntyre DE, Forrest M, et al: Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. The special case of Streptococcus pneumoniae. J Clin Invest 1992; 90: 612-618
9. Graham RM, Stephens CJ, Silvester W, et al: Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 1994; 22:204-212
10. Saunders RN, Handley DA: Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol 1987; 27:237-255
11. Koltai M, Osford D, Guinot P, et al: Platelet activating factor. A review of its effects, antagonists and possible future clinical applications (Part I). Drugs 1991; 42:9-29
12. Koltai M, Osford D, Guinot P, et al: Platelet activating factor. A review of its effects, antagonists and possible future clinical applications (Part II). Drugs 1991; 42:174-204
13. Dhainaut JF, Mira JP, Brunet F: Platelet-activating factor antagonists as therapeutic strategy in sepsis. In: Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies. Levin J, van Deventer SJH, van der Poll T, et al (Eds). New York, Wiley-Liss, 1994, pp 277-293
14. Etienne A, Hecquet F, Soulard C, et al: In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific platelet-activating factor-acether antagonist: BN 52021. Agents Actions 1985; 17:368-370
15. Adnot S, Lefort J, Lagente V, et al: Interference of BN 52021, a platelet-activating factor-acether antagonist, with endotoxin-induced hypotension in the guinea-pig. Pharmacol Res Commun 1986; 18:197-200
16. Etienne A, Hecquet F, Soulard C, et al: Inhibition of rat endotoxin-induced lethality by BN 52021 and BN 52063, compounds with platelet-activating factor-acether antagonistic effect and protease-inhibitory activity. Int J Tissue React 1987; 9:19-26
17. Rabinovici R, Yue TL, Farhat M, et al: Platelet-activating factor and TNF interactions in endotoxemic shock: Studies with BN 50739, a novel platelet-activating factor antagonist. J Pharmacol Exp Ther 1990; 255: 258-263
18. Feuerstein G, Leader P, Siren AL, et al: Protective effect of a platelet-activating factor-acether antagonist, BN 52021, in trichothecene toxicosis. Toxicol Lett 1987; 38:271-274
19. Duchier J, Cournot A, Hosford D, et al: Clinical studies on the tolerance and effects of BN 52021 on PAF-induced platelet aggregation and skin reactivity in healthy volunteers. In: Ginkgolides-Chemistry, Biology, Pharmacology, and Clinical Perspectives. Vol 2. Braquet P (Ed). Barcelona, Spain, Prous Science Publishers, 1989, pp 897-904
20. Nathan N, Mercury P, Denizot Y, et al: Effects of the platelet-activating factor receptor antagonist BN 52021 on hematologic variables and blood loss during and after cardiopulmonary bypass. Anesth Analg 1994; 79:205-211
21. Grino JM for the BN 52021 study group in renal transplantation: BN 52021, a platelet-activating factor antagonist, to prevent post-transplant renal failure. Ann Intern Med 1994; 121:345-347
22. Brocher B, Guinot P, Orgogozo JM, et al: Double blind placebo controlled multicentre study of ginkgolide B on treatment of acute exacerbations of multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 58:360-362
23. Dhainaut JFA, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1995; 22:1720-1728
24. Björk L, Andersson J, Ceska M, et al: Endotoxin and Staphylococcus aureus enterotoxin-A induce different patterns of cytokines. Cytokine 1992; 4:513-519
25. Fisher CJ, Dhainaut JFA, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist reduces the mortality of patients with septic syndrome as a function of disease severity: A randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-1843
26. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
27. Bone RC, Fisher CJ, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17: 389-393
28. Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiologic score (SAPS II) based on a European-North American multicenter study. JAMA 1993; 270:2957-2963
29. McCabe WR, Jackson GG: Gram negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110: 845-855
30. Murray JF, Matthay MA, Luce JM, et al: An expanded definition of the ARDS. Am Rev Respir Dis 1988; 138:720-723
31. Wenzel RP: Anti-endotoxin monoclonal antibodies - A second look. N Engl J Med 1992; 326:1151-1153
32. Cross AS: Anti-endotoxin antibodies: A dead end? Ann Intern Med 1994; 121:58-60
33. Abraham E, Raffin TA: Sepsis therapy trials: Continued disappointment or reason for hope? JAMA 1994; 271: 1876-1878
34. Opal SM: Lessons learned from clinical trials of sepsis. J Endotoxin Res 1995; 2:221-226
35. Sibbald WJ, Vincent JL: Roundtable conference on clinical trials for the treatment of sepsis. Crit Care Med 1995; 23:394-399
36. Fink MP: Another negative clinical trial for a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatment for serious infections. Crit Care Med 1995; 223:989-991
37. Milberg JA, Davis DR, Steinberg KP, et al: Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273:306-309
38. Pittet D, Tarara D, Wenzel RP: Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra-costs, and attributable mortality. JAMA 1994; 271:1596-1601
39. Sprung CL, Eidelman LA, Pizov R, et al: Influence of alterations in forgoing life-sustaining treatment practices on a clinical sepsis trial. Crit Care Med 1997; 25:383-387
40. Cohen J, Carlet J, INTERSEPT Study Group: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24:1431-1440
41. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human TNF-α in patients with sepsis syndrome. JAMA 1995; 273:934-941
42. Abraham E, Glauser MP, Butler T, et al: P55 TNF factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 1997; 277:1531-1538
43. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912-918.
44. Knaus WA, Sun X, Nystrom PO, et al: Evaluation of definition for sepsis. Chest 1992; 101:1656-1662
45. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. From the bench to the bedside: The future of sepsis research. Chest 1997; 111: 744-753